​

Relay Therapeutics (RLAY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RLAY Stock Forecast

Relay Therapeutics (RLAY) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $24.00, with a high of $28.00 and a low of $18.00. This represents a 77.91% increase from the last price of $13.49.

- $6 $12 $18 $24 $30 High: $28 Avg: $24 Low: $18 Last Closed Price: $13.49

RLAY Stock Rating

Relay Therapeutics stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 1 Strong Buy (6.67%), 14 Buy (93.33%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 14 1 Strong Sell Sell Hold Buy Strong Buy

RLAY Price Target Upside V Benchmarks

TypeNameUpside
StockRelay Therapeutics77.91%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4911
Avg Price Target$26.75$23.89$22.00
Last Closing Price$13.49$13.49$13.49
Upside/Downside98.30%77.09%63.08%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26211---13
May, 262101--13
Apr, 26210---12
Mar, 26110---11
Feb, 26210---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 26, 2026Brad CaninoGuggenheim$26.00$13.5392.17%92.74%
May 26, 2026H.C. Wainwright$28.00$13.53106.95%107.56%
May 20, 2026Barclays$27.00$12.07123.70%100.15%
May 19, 2026UBS$26.00$12.88101.86%92.74%
Apr 29, 2026H.C. Wainwright$25.00$13.0391.86%85.32%
Apr 28, 2026Oppenheimer$18.00$14.9520.40%33.43%
Apr 28, 2026Wells Fargo$21.00$14.9540.47%55.67%
Apr 28, 2026Salveen RichterGoldman Sachs$22.00$14.9547.16%63.08%
Mar 13, 2026Brad CaninoGuggenheim$22.00$10.81103.52%63.08%
Jan 26, 2026Oppenheimer$14.00$7.4388.43%3.78%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 26, 2026GuggenheimBuyBuyhold
May 26, 2026H.C. WainwrightBuyBuyhold
May 20, 2026CitigroupOutperformOutperformhold
May 20, 2026BarclaysOverweightOverweighthold
May 19, 2026Raymond JamesStrong BuyStrong Buyhold
Apr 29, 2026H.C. WainwrightBuyBuyhold
Apr 28, 2026OppenheimerOutperformOutperformhold
Apr 28, 2026Wells FargoOverweightOverweighthold
Apr 28, 2026Goldman SachsBuyBuyhold
Apr 28, 2026CitigroupOutperformOutperformhold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.82$-2.59$-2.79$-2.36$-1.61---
Avg Forecast$-3.69$-2.74$-2.83$-2.52$-2.64$-2.55$-2.48$-1.68
High Forecast$-3.08$-0.68$-2.76$-2.29$-2.20$-1.85$-1.99$0.34
Low Forecast$-4.55$-11.03$-2.93$-2.71$-3.21$-3.01$-2.80$-4.72
Surprise %3.52%-5.47%-1.41%-6.35%-39.02%---

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.03M$1.38M$25.55M$10.01M$15.36M---
Avg Forecast$6.41M$4.46M$24.30M$15.08M$3.52M$20.47M$24.95M$152.86M
High Forecast$7.57M$14.83M$30.45M$48.43M$8.39M$48.83M$25.85M$364.65M
Low Forecast$5.60M$1.88M$1.17M$8.07M$268.42K$1.56M$24.06M$11.67M
Surprise %-52.76%-69.02%5.13%-33.64%336.69%---

Net Income Forecast

$-700M $-550M $-400M $-250M $-100M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-363.87M$-290.51M$-341.97M$-337.71M$-276.48M---
Avg Forecast$-579.15M$-258.70M$-341.97M$-306.66M$-331.40M$-297.78M$-293.44M$-206.34M
High Forecast$-463.32M$-206.96M$-273.58M$-280.65M$-269.85M$-226.94M$-243.93M$41.42M
Low Forecast$-694.98M$-310.43M$-410.37M$-332.66M$-392.94M$-368.62M$-342.95M$-577.98M
Surprise %-37.17%12.30%-10.13%-16.57%---

RLAY Forecast FAQ

Is Relay Therapeutics stock a buy?

Relay Therapeutics stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 14 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Relay Therapeutics is a favorable investment for most analysts.

What is Relay Therapeutics's price target?

Relay Therapeutics's price target, set by 15 Wall Street analysts, averages $24 over the next 12 months. The price target range spans from $18 at the low end to $28 at the high end, suggesting a potential 77.91% change from the previous closing price of $13.49.

How does Relay Therapeutics stock forecast compare to its benchmarks?

Relay Therapeutics's stock forecast shows a 77.91% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Relay Therapeutics over the past three months?

  • June 2026: 15.38% Strong Buy, 84.62% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 15.38% Strong Buy, 76.92% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Relay Therapeutics’s EPS forecast?

Relay Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.55, marking a 58.39% increase from the reported $-1.61 in 2025. Estimates for the following years are $-2.48 in 2027, and $-1.68 in 2028.

What is Relay Therapeutics’s revenue forecast?

Relay Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $20.47M, reflecting a 33.31% increase from the reported $15.36M in 2025. The forecast for 2027 is $24.95M, and $152.86M for 2028.

What is Relay Therapeutics’s net income forecast?

Relay Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-298M, representing an 7.70% increase from the reported $-276M in 2025. Projections indicate $-293M in 2027, and $-206M in 2028.